Monoclonal antibody achieves best results for chronic lymphocytic leukemia

June 03, 2003

CHICAGO -- Pairing chemotherapy with the new monoclonal antibody, Rituximab, delivers the most effective treatment yet for chronic lymphocytic leukemia, say researchers at The University of Texas M. D. Anderson Cancer Center.

Results of their large 202-patient study, presented at the annual meeting of the American Society of Clinical Oncology, demonstrate a complete remission rate of 69 percent, the highest rate ever achieved, the researchers say.

"The study has been accruing patients over a four year period. Not only are the remissions very frequent and of a long duration, in almost half of the responding patients we can't find any evidence of disease using the most sensitive techniques available," says lead investigator, Michael Keating, M.D., professor in the Department of Leukemia.

"I am most optimistic about this combination therapy, and it is now the cornerstone of treatment at M. D. Anderson for our patients with this leukemia, both as initial treatment and when previous treatment has failed," Keating says.

Chronic lymphocytic leukemia (CLL), a cancer of the blood, is the second most commonly diagnosed type of leukemia. It is caused by the overproduction of immature blood cells in the bone marrow which crowd out healthy cells needed to fight infection and deliver oxygen to the body. CLL progresses slowly, and it may take years for symptoms to appear or for treatment to be needed.

Typically, chemotherapy is used to treat the cancer, but with limited success. This clinical trial was the first major study using a combination of two chemotherapy drugs (Fludarabine and Cyclophosphamide) with Rituximab, a monoclonal antibody drug that has been federally approved for use in non-Hodgkin's lymphoma.

Monoclonal antibodies are designed to hook onto proteins found on the surface of cancer cells and trigger an immune response against the cells. According to Keating, the combination is usually given to patients outside of the hospital and makes leukemia cells more sensitive to the effects of chemotherapy. "It is clear that Rituximab is adding significantly to treatment."

"This appears to work in all age groups and in all stages of the leukemia," he says. "Even patients older than age 70 have a response rate of more than 80 percent with 40 percent to 45 percent achieving a complete remission, which was formerly uncommon in this age group."
-end-
Contact: Stephanie Dedeaux or Laura Sussman, 713/792-0655

University of Texas M. D. Anderson Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.